[go: up one dir, main page]

WO2002036623A3 - Ghep, a gene highly expressed in normal and neoplastic prostate, and uses therefor - Google Patents

Ghep, a gene highly expressed in normal and neoplastic prostate, and uses therefor Download PDF

Info

Publication number
WO2002036623A3
WO2002036623A3 PCT/US2001/042627 US0142627W WO0236623A3 WO 2002036623 A3 WO2002036623 A3 WO 2002036623A3 US 0142627 W US0142627 W US 0142627W WO 0236623 A3 WO0236623 A3 WO 0236623A3
Authority
WO
WIPO (PCT)
Prior art keywords
prostate
proteins
gene
ghep
normal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/042627
Other languages
French (fr)
Other versions
WO2002036623A2 (en
Inventor
Ira H Pastan
Par Olsson
Tapan K Bera
Magnus Essand
Byungkook Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Priority to AU2002230400A priority Critical patent/AU2002230400A1/en
Publication of WO2002036623A2 publication Critical patent/WO2002036623A2/en
Anticipated expiration legal-status Critical
Publication of WO2002036623A3 publication Critical patent/WO2002036623A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention provides a Gene Highly Expressed in Prostate ('GHEP'). The gene is found in normal and neoplastic prostate, and encodes two short proteins, one 34 amino acids ('ghep34') in length and one 35 amino acids in length ('ghep35'). Detection of the transcript or of the proteins in tissues other than the prostate, liver, or salivary gland is indicative of prostate cancer. The nucleic acids, proteins, and immunogenic fragments thereof can be used to raise an immune response to prostate cancer. The invention further provides methods of detecting the proteins or the gene transcript in a biological sample. If the biological sample is from a tissue other than the prostate, liver or salivary gland, detection of either of the protein or of the gene transcript is indicative of the presence of prostate cancer in the subject from whom the sample was taken. The invention further provides antibodies which specifically recognize ghep34 and antibodies which specifically recognize ghep35, as well as kits for the detection of one or both of the proteins in a sample.
PCT/US2001/042627 2000-10-10 2001-10-10 Ghep, a gene highly expressed in normal and neoplastic prostate, and uses therefor Ceased WO2002036623A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002230400A AU2002230400A1 (en) 2000-10-10 2001-10-10 Ghep, a gene highly expressed in normal and neoplastic prostate, and uses therefor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23941300P 2000-10-10 2000-10-10
US60/239,413 2000-10-10

Publications (2)

Publication Number Publication Date
WO2002036623A2 WO2002036623A2 (en) 2002-05-10
WO2002036623A3 true WO2002036623A3 (en) 2003-12-11

Family

ID=22902023

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/042627 Ceased WO2002036623A2 (en) 2000-10-10 2001-10-10 Ghep, a gene highly expressed in normal and neoplastic prostate, and uses therefor

Country Status (2)

Country Link
AU (1) AU2002230400A1 (en)
WO (1) WO2002036623A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1033401A2 (en) * 1999-02-26 2000-09-06 Genset Expressed sequence tags and encoded human proteins
WO2000055174A1 (en) * 1999-03-12 2000-09-21 Human Genome Sciences, Inc. Human prostate cancer associated gene sequences and polypeptides
WO2001007476A1 (en) * 1999-07-21 2001-02-01 Human Genome Sciences, Inc. 26 human prostate and prostate cancer associated proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1033401A2 (en) * 1999-02-26 2000-09-06 Genset Expressed sequence tags and encoded human proteins
WO2000055174A1 (en) * 1999-03-12 2000-09-21 Human Genome Sciences, Inc. Human prostate cancer associated gene sequences and polypeptides
WO2001007476A1 (en) * 1999-07-21 2001-02-01 Human Genome Sciences, Inc. 26 human prostate and prostate cancer associated proteins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE SWALL [online] 1 November 1998 (1998-11-01), FRASER CM ET AL.: "Nitrogen fixation protein (NIFU).", XP002213918, retrieved from EBI Database accession no. O83624 *
OLSSON PAR ET AL: "GDEP, a new gene differentially expressed in normal prostate and prostate cancer.", PROSTATE, vol. 48, no. 4, 1 September 2001 (2001-09-01), pages 231 - 241, XP001104096, ISSN: 0270-4137 *
VASMATZIS G: "Discovery of three genes specifically expressed in human prostate by expressed sequence tag database analysis", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 95, January 1998 (1998-01-01), pages 300 - 304, XP002151634, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
AU2002230400A1 (en) 2002-05-15
WO2002036623A2 (en) 2002-05-10

Similar Documents

Publication Publication Date Title
WO1997033996A3 (en) Human bikunin
WO2001036470A3 (en) Methods and compositions for detection and treatment of breast cancer, based on breast cancer-associated polypeptides
WO2002020569A3 (en) Mammalian genes; related reagents and methods
WO1995016919A3 (en) Methods and compositions for the detection of colon cancers
EP2330129A3 (en) Anti-TNF antibodies, compositions, methods and uses
WO2001072976A3 (en) 32142, 21481, 25964, 21686, novel human dehydrogenase molecules and uses therefor
WO2004024750A3 (en) Cd44-binding ligands
WO2002029086A3 (en) Nucleic acid sequences differentially expressed in cancer tissue
WO2002008767A3 (en) Methods and kits for sequencing polypeptides
WO1997029199A3 (en) Prostate specific antigen peptides and uses thereof
AU2002223044A1 (en) Kit and method for detecting the esm-1 protein
WO2000035950A3 (en) Reagents and methods useful for detecting diseases of the breast
AU3623197A (en) Peptide reagent for the detection of human cytomegalovirus (cmv)
EP1108789A3 (en) Quantitation of hTERT mRNA Expression
SE0000675D0 (en) Monoclonal antibodies
EP1136547A3 (en) Adamts polypeptides, nucleic acids encoding them, and uses thereof
WO2001056456A3 (en) Methods and compositions for detection of disease
WO2002014361A3 (en) NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 83P2H3 AND CaTrF2E11 USEFUL IN TREATMENT AND DETECTION OF CANCER
WO2002036623A3 (en) Ghep, a gene highly expressed in normal and neoplastic prostate, and uses therefor
EP1134286A3 (en) Adamts polypeptides, nucleic acids encoding them, and uses thereof
WO2002002771A3 (en) Human sparc-homologous (hsparc-h1) gene and methods and uses thereof
WO2001079489A8 (en) 39228, a human alcohol dehydrogenase and uses therefor
WO2001065262A3 (en) Reagents and methods useful for detecting diseases of the breast
WO2004094989A3 (en) Methods of host cell protein analysis
WO2002030977A3 (en) Egf motif protein, egfl6 materials and methods

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP